{"id":"9ada6f51-4b62-572e-bd93-1262bedce8cb","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-the-two-reads-disagree","predicate":"increases","statement":"Compared to control treatment the addition of BTH1677 numerically increased objective response rate by both investigator review at 47.8% versus 23.1% with p=0.0468 and central review at 36.6% versus 23.1% with p=0.2895, no other endpoints differed between arms, BTH1677 was well tolerated with adverse events expected of the backbone therapy predominating, and biomarker-positive patients displayed better objective response rate and overall survival than negative patients.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"a9a34b20-6395-5f5c-a289-cf5cdf263528","mechanism_event_label":"The doctors running the trial saw twice the response rate; the blinded reviewers saw a smaller difference that could have been chance.","subject":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"object":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"a9a34b20-6395-5f5c-a289-cf5cdf263528","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-the-two-reads-disagree-event","event_type":"observed_intervention","label":"The doctors running the trial saw twice the response rate; the blinded reviewers saw a smaller difference that could have been chance.","description":"Compared to control treatment the addition of BTH1677 numerically increased objective response rate by both investigator review at 47.8% versus 23.1% with p=0.0468 and central review at 36.6% versus 23.1% with p=0.2895, no other endpoints differed between arms, BTH1677 was well tolerated with adverse events expected of the backbone therapy predominating, and biomarker-positive patients displayed better objective response rate and overall survival than negative patients.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"afe6f619-e984-533b-b63a-83b4e77aab4f","slug":"anti-beta-glucan-antibodies","display_name":"Naturally occurring anti-beta-glucan IgG antibodies","entity_type_key":"protein"},"role":"proposed_biomarker","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d3889da6-26a5-53db-8524-995e87aa75ba","slug":"antitumour-monoclonal-antibody","display_name":"Complement-activating antitumour monoclonal antibodies","entity_type_key":"protein"},"role":"backbone_therapy","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/28303530.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1647608a80fde3f663b90783006859ae85ed15bc718a8d9031ba5acdb586eb7b\", \"start_char\": 0, \"end_char\": 2002, \"text_sha256\": \"1647608a80fde3f663b90783006859ae85ed15bc718a8d9031ba5acdb586eb7b\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomised open-label multicentre phase II trial with both investigator and blinded central radiology review","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"BTH1677 4 milligrams per kilogram weekly with cetuximab, carboplatin and paclitaxel against the same backbone alone, randomised 2 to 1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Ninety patients, open-label, with the primary response endpoint read twice. The two reads disagree, which is the finding.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The doctors running the trial saw twice the response rate; the blinded reviewers saw a smaller difference that could have been chance.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p28303530] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. (2017). https://pubmed.ncbi.nlm.nih.gov/28303530/ DOI: 10.1007/s10637-017-0450-3","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Advanced non-small cell lung cancer","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ad2ea783-3864-57c2-af7f-c75d13fee3ce","evidence_kind":"source_excerpt","locator":"Lines 307-318","start_line":307,"end_line":318,"excerpt":"### bg-the-two-reads-disagree\nCompared to control treatment the addition of BTH1677 numerically increased objective response rate by both investigator review at 47.8% versus 23.1% with p=0.0468 and central review at 36.6% versus 23.1% with p=0.2895, no other endpoints differed between arms, BTH1677 was well tolerated with adverse events expected of the backbone therapy predominating, and biomarker-positive patients displayed better objective response rate and overall survival than negative patients.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: The doctors running the trial saw twice the response rate; the blinded reviewers saw a smaller difference that could have been chance.\norganism: Human\ntissue_or_cell_type: Advanced non-small cell lung cancer\nexperimental_model: Randomised open-label multicentre phase II trial with both investigator and blinded central radiology review\nlimitations: Ninety patients, open-label, with the primary response endpoint read twice. The two reads disagree, which is the finding.\nexposure: BTH1677 4 milligrams per kilogram weekly with cetuximab, carboplatin and paclitaxel against the same backbone alone, randomised 2 to 1\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/28303530.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1647608a80fde3f663b90783006859ae85ed15bc718a8d9031ba5acdb586eb7b\", \"start_char\": 0, \"end_char\": 2002, \"text_sha256\": \"1647608a80fde3f663b90783006859ae85ed15bc718a8d9031ba5acdb586eb7b\"}\n[bg-p28303530] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. (2017). https://pubmed.ncbi.nlm.nih.gov/28303530/ DOI: 10.1007/s10637-017-0450-3","model_system":"Randomised open-label multicentre phase II trial with both investigator and blinded central radiology review","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p28303530] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. (2017). https://pubmed.ncbi.nlm.nih.gov/28303530/ DOI: 10.1007/s10637-017-0450-3","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}